已收盘 02-06 16:00:00 美东时间
+0.120
+2.54%
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
2025-11-13 09:58
Lifezone Metals (NYSE:LZM) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 42.86 percent increase over losses of $(0.14) per share from
2025-08-12 04:36
Lifezone Metals ( ($LZM) ) just unveiled an update. Lifezone Metals Limited ann...
2025-07-18 18:57
<span> <meta content="no-referrer" name="referrer"></span><img src="https://r.hstong.com/public/cms/images/2024/12/19/20241219084201089.png" referrerpolicy="no-referrer"><figure class="table" style="overflow-x: scroll;"> <table> <tbody> <tr> <td>标的</td> <td>代码</td> <td>评级</td> <td>目标价</td> <td>当前价</td> <td>潜在涨跌幅</td> <td>机构名称</td> </tr> <tr> <td>TransCode Therapeutics Inc Ordinary Shares</td> <td
2024-12-19 09:43
Lifezone Metals (NYSE:LZM) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.05) by 180 percent.
2024-08-19 20:11